DDInter1042 DDInter51
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Alogliptin {u} (Compound) resembles {v} (Compound) Linagliptin
Alogliptin {u} (Compound) binds {v} (Gene) CYP2D6
Alogliptin {u} (Compound) is included by {v} (Pharmacologic Class) Dipeptidyl Peptidase 4 Inhibitors
Alogliptin {u} (Compound) causes {v} (Side Effect) Pancreatitis
Alogliptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Alogliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrochlorothiazide
Alogliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Alogliptin {u} may lead to a major life threatening interaction when taken with {v} Gatifloxacin
Alogliptin (Compound) resembles Linagliptin (Compound)
Alogliptin (Compound) binds CYP2D6 (Gene)
Alogliptin (Compound) is included by Dipeptidyl Peptidase 4 Inhibitors (Pharmacologic Class)
Alogliptin (Compound) causes Pancreatitis (Side Effect)
Alogliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Alogliptin may lead to a major life threatening interaction when taken with Gatifloxacin